SequelSEC

BioCardia, Inc. BCDA

Biological Products, (No Diagnostic Substances) · CIK 0000925741 · Fiscal year ends 1231

Revenue
$0
Fiscal year ended 2025-12-31
Operating income
-$8.28M
Fiscal year ended 2025-12-31
Free cash flow
-$7.44M
Fiscal year ended 2025-12-31

Valuation, from the filing

Public float$9.70MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.89Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / equity10.8×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Biological Products, (No Diagnostic Substances) filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Revenue YoY growth-100.0%0th
Current ratio1.12x19th

BioCardia, Inc. (BCDA) reported revenue of $0 and net income of -$8.23M for the fiscal year ended 2025-12-31. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from BioCardia, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

BioCardia, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
Revenue$0
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$8.28M
Net income-$8.23M
Research & development$4.96M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expense$0
Diluted EPSUnavailable
Selling, general & administrative$3.32M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

BioCardia, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
Cash & equivalents$2.50M
Total assets$3.41M
Current assets$2.73M
Total liabilities$2.52M
Current liabilities$2.43M
Total equity incl. NCI$895.00K
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivable$20.00K
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$641.00K

Cash flow

BioCardia, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
Operating cash flow-$7.44M
Capital expenditures$7.00K
Investing cash flow-$7.00K
Financing cash flow$7.57M
Net change in cash$125.00K
Stock-based compensation$430.00K
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$24.00K

Derived

BioCardia, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
Free cash flow-$7.44M
Gross marginUnavailable
Operating marginUnavailable
FCF marginUnavailable
SBC / revenueUnavailable
Current ratio1.12x
Revenue YoY growth-100.0%
Net marginUnavailable
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BCDA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-12View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-03-24View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q/A · Filed 2025-10-29View SEC filing
10-Q · Filed 2025-08-11View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.